A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00058526
First received: April 7, 2003
Last updated: July 18, 2013
Last verified: July 2013